News | June 11, 2024
Abbott wins CE mark for dual-chamber leadless pacemaker
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
Subscribe To Our Newsletter & Stay Updated
